Waiting
Login processing...

Trial ends in Request Full Access Tell Your Colleague About Jove

Assessing Genomic Alteration in Non-Squamous Non-Small Cell Lung Cancer Patients

September 8th, 2023
1,2,3,4,5, 1,2,3,4, 1,2,3,4, 1,2,3,4, 1,2,3,4, 1,2,3,4, 1,2,3,4, 1,2,3,4, 3,4,5,6, 3,4,5,6, 1,2,3,4,5, 1,2,3,4,5, 1,2,3,4,5
1Laboratory of Clinical and Experimental Pathology, Centre Hospitalier Universitaire de Nice, Université Côte d’Azur, CHU de Nice, 2Hospital-Integrated Biobank (BB-0033-00025), Université Côte d'Azur, Hôpital Pasteur, CHU de Nice, 3Institut Hospitalo-Universitaire (IHU), RespirERA, Université Côte d'Azur, Hôpital Pasteur, CHU de Nice, 4FHU OncoAge, Université Côte d'Azur, 5Team 4, Institute of Research on Cancer and Aging (IRCAN), CNRS INSERM, Centre Antoine-Lacassagne, Université Côte d'Azur, 6Department of Pulmonary Medicine and Thoracic Oncology, Centre Hospitalier Universitaire de Nice, Université Côte d'Azur

Summary
Automatic Translation

The increase of molecular biomarkers to be tested for non-squamous non-small cell lung cancer (NS-NSCLC) care management has prompted the development of fast and reliable molecular detection methods. We describe a workflow for genomic alteration assessment for NS-NSCLC patients using an ultra-fast-next generation sequencing (NGS) approach.

Article

Get cutting-edge science videos from JoVE sent straight to your inbox every month.

Waiting X
Simple Hit Counter